Loss of response to infliximab in patients with perianal fistulizing Crohn's disease:a case report
10.12173/j.issn.1005-0698.202405039
- VernacularTitle:1例对英夫利西单抗失应答肛瘘型克罗恩病患者的病例分析
- Author:
Mengke WANG
1
;
Hefeng CHEN
Author Information
1. 河南大学淮河医院药学部(河南开封 475000)
- Keywords:
Perianal fistulizing Crohn's disease;
Infliximab;
Loss of response;
Ustekinumab
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(8):949-954
- CountryChina
- Language:Chinese
-
Abstract:
A refractory Crohn's disease patient with recurrent perianal fistulas failed to overcome the secondary loss of response to infliximab(IFX)after therapeutic drug monitoring,intensified anti-TNF dosing and in combination with azathioprine.Throughout the treatment process,clinical pharmacists assisted physicians in analyzing the risk factors and causes for loss of response,providing evidence for an individualized treatment strategy,and monitoring the efficacy and safety of the treatment.According to the relevant guidelines and literature,ustekinumab was the preferred biological agent after anti-TNF failure in perianal fistulizing Crohn's disease(pfCD).At the 12-week follow-up,fecal calprotectin and C-reactive protein decreased markedly,and the patient achieved fistula healing.This case provides references for current management strategy and perspective in IFX secondary non-responders with refractory pfCD,especially those who have undergone optimization therapy.
